Journal
NANOSCALE
Volume 14, Issue 12, Pages 4588-4594Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/d1nr07750c
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [61805161]
- Natural Science Foundation of Guangdong Province [2021A1515010441]
- Ka Shing Foundation Cross-Disciplinary Research Grant [2020LKSFG05C]
- U.S. National Institutes of Health [R01CA205348]
- Oklahoma Center for the Advancement of Science and Technology [HR16-085, HF20-019]
Ask authors/readers for more resources
Chemotherapy often suppresses the immune system, limiting its effectiveness. By designing a novel nanocarrier to deliver an anticancer drug, the immune system can be restored and the effectiveness of chemotherapy can be improved. Additionally, this nanocarrier can also serve as a contrast agent for magnetic resonance imaging of tumors and lymph nodes.
Chemotherapy is still regarded as the main modality for cancer treatment. However, it often suppresses the host immune system, resulting in limited therapeutic effects. It is desirable to design a novel chemotherapeutic agent to reduce the level of immunosuppression. Herein, we designed bovine serum albumin (BSA)-bioinspired iron oxide nanoparticles (IONPs) as a nanocarrier to load anticancer drug mitoxantrone (MTX) for enhanced chemotherapy of orthotopic breast cancer. The treatment with IONPs@BSA-MTX complexes increased CD3(+)CD4(+) and CD3(+)CD8(+) T lymphocytes more than free MTX. The complexes effectively restored the host immune system and exhibited a better anticancer efficacy than free MTX. It was worth noting that the BSA-inspired IONPs were a satisfactory contrast agent for magnetic resonance imaging of tumors and lymph nodes. Our work provides a novel strategy for enhanced chemotherapy with low levels of immunosuppression in the treatment of breast cancer and other cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available